Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Inks Deals with Celera, Biogen; Will Integrate DecisionSite with CDS

NEW YORK, April 9 – Spotfire said Monday that it has signed agreements with both Celera and Biogen for use of Spotfire’s DecisionSite analytical software.

Celera and Spotfire will integrate DecisionSite, which enables visual analysis of product, process, and customer information from a variety of sources, with the Celera Discovery System, which provides access to Celera’s human, mouse, and fly genomes as well as other biological databases. 

Users will be able to move between DecisionSite and CDS in order to add genomic and biomedical information from CDS to their own data and experiment results. 

Biogen has licensed DecisionSite to help its researchers access, analyze, and share data and collaborate across teams, departments, and geographies in the drug discovery and development process.

Financial terms of the agreements were not disclosed. 

"We recognize that one of the key next challenges in the  genome  race is to equip decision makers with an integrated user experience into  genomics , chemistry, and screening data. Spotfire DecisionSite gives us this ability, resulting in a substantial competitive advantage," said Rainer Fuchs, senior director of research informatics at Biogen, in a statement. 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.